Dr Belinda Quinn is a trained medical doctor, a specialised clinical researcher in neurology and a commercially focused Director. She joined the Precision Medicine Catapult (PMC) in 2015 as Chief Clinical Officer and became Chief Executive Officer in April 2016.
Before joining the PMC, Belinda was interim Director for MHRA where she led teams of researchers, scientists and IT specialists using technology to establish Pragmatic Real World studies for pharma.
As Executive Director for a UK hospital, Belinda was responsible for delivering clinical and IT risk reviews. She delivered ‘best of breed’ solutions, allowing the hospital to operate with unmatched security, reliability and flexibility. Belinda has held senior roles in public healthcare both in the UK and Australia and has been a Vice President of GlaxoSmithKline and Associate Partner at Accenture.
Professor Joanne Hackett has been actively involved in clinical research for over 15 years in Canada, America, Germany, Sweden and the UK. She joined the PMC in October 2016.
An accomplished entrepreneur, scientist and strategist, Joanne has experience in the execution and management of complex business transactions, as well as broad business development experience in negotiation, execution and management of hundreds of transactions with pharma, biotech, academia and non-profits organisations.
Dr Ruth Jamieson is seconded to the PMC from University College London (UCL) where she has spent the last five years involved in the strategic development of initiatives and funding bids and for experimental and personalised medicine. At the Catapult, Ruth’s role is to identify and assess precision medicine opportunities across the London academic, research and health landscape, and then identify those that best meet the criteria for the PMC to support and advance in line with the PMC’s emerging 5-year strategy and plan.
Ruth holds a PhD in Medical Genetics from St George’s Hospital Medical School, University of London. Following her academic career, Ruth moved into science funding, spending 11 years at the Wellcome Trust as a Science Portfolio Adviser working on a wide range of bioscience before joining UCL.